More investment for Intelligent Fingerprinting mobile drug screening solution

February 2, 2016 - 

In its latest funding round, UK-based Intelligent Fingerprinting has raised £2.5 million ($3.6M USD) investment from private UK and US investors, according to a report by Business Weekly.

Intelligent Fingerprinting’s mobile drug screening device collects and analyzes sweat from an individual’s fingerprint to provide data on recent drug use, achieving results in under ten minutes. Last October, the company presented evaluation data from its pilot project testing the potential use of its new mobile drug screening device by coroners and mortuary staff to collect early intelligence about cause of death.

To date, the company had raised approxiametly £8.73M ($12.6M USD) of private investment over four years including original seed funding of £0.5m.

The funding will provide working capital to complete the development of the company’s first products and to begin manufacturing at its new location in Cambridge.

“This timely new investment represents another step forward for our company,” said Dr Jerry Walker, chief executive officer. “It allows us to finalise our revolutionary mobile drug screening technology for market and begin the manufacturing process to meet early demand for the first of our planned fingerprint-based products.”

Intelligent Fingerprinting has also secured several government-funded grants from the EUREKA Eurostars Programme (administered by Innovate UK) and funding for pilot studies within the UK’s National Health Service and coroners’ services.

The company says its solution has potential for use in drug rehabilitation services, offender management, criminal justice and occupational health and safety.

Leave a Comment

comments

About Stephen Mayhew

Stephen Mayhew is the publisher and co-founder of Biometrics Research Group, Inc.. His experience includes a mix of entrepreneurship, brand development and publishing. Stephen attended Carleton University and lives in Toronto, Canada. Connect with Stephen on LinkindIn.